Cannabidiol : a hope to treat non‑motor symptoms of Parkinson’s disease patients Sidra Saleem & Arsalan Anwar European Archives of Psychiatry and Clinical Neuroscience, 2019 https://doi.org/10.1007/s00406-019-01023-y We read an article, “Is Cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms” by Cripp [1], the novel discussion and explanation of the role of cannabidiol (CBD) in Parkinson’s disease (PD) inspired us to write our feedback. We would like to share our views on the role of CBD in the prevention and treatment of movement disorders. CBD is one of the main components of Cannabis sativa investigated previously for its neuroprotective effects. Its mechanism of action [...]
Lire la suiteMental health of a self-selected sample of psychedelic users and self-medication practices with psychedelics Natasha L. MASON and Kim P. C. KUYPERS Journal of Psychedelic Studies, 2018, 2, (1), pp. 45–52 DOI: 10.1556/2054.2018.006 Background : A substantial number of people worldwide suffer from mental health problems during their lifetime. First-line treatments are not effective for everybody. Recent studies suggest that psychedelic drugs have high therapeutic potential for a variety of mental disorders. Aims : This survey study aimed to assess the tendency of psychedelic users to self-medicate with psychedelics and to compare the effectiveness of self-administered psychedelics to treat their disorder and the treatment offered [...]
Lire la suiteInside bad trips : Exploring extra-pharmacological factors Genis ONA Journal of Psychedelic Studies, 2018, 2, (1), pp. 53–60 DOI: 10.1556/2054.2018.001 Objective : This study aimed to clarify the influence of extra-pharmacological factors in the etiology of bad trips, a common adverse reaction related to the consumption of psychedelic drugs. Methods : A descriptive approach was adopted. The information was collected using a web-based survey. The survey respondents volunteered to participate based on the condition that they had suffered a bad trip in the past. Results : This report reveals some variables that are commonly related to this adverse reaction (i.e., the recreational consumption of drugs, the [...]
Lire la suiteA phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment EDUARDO EKMAN SCHENBERG, MARIA ANGÉLICA DE CASTRO COMIS, JOÃO FELIPE MOREL ALEXANDRE, LUÍS FERNANDO TÓFOLI, BRUNO DANIEL RASMUSSEN CHAVES, DARTIU XAVIER DA SILVEIRA Journal of Psychedelic Studies, 2017, 1, (2), pp. 74–83 DOI: 10.1556/2054.01.2017.007 Objective : This report documents the phenomenology of the subjective experiences of 22 patients with substancerelated disorders who were involved in a treatment combining cognitive–behavioral therapy and hospital sessions with ibogaine in Brazil. Methods: Participants underwent a one-to-one semi structured interview exploring the subjective effects of ibogaine. We employed interpretative phenomenological analysis [...]
Lire la suitePerceptions of the medicinal value of hallucinogenic drugs among college students JARED I. WILDBERGER, CASSANDRA N. JOHN and ROBERT M. HALLOCK Journal of Psychedelic Studies, 2017, 1(2), pp. 50–54 DOI: 10.1556/2054.01.2017.008 Background : This survey examined perceptions among college students about the potential medicinal benefits of hallucinogenic drugs. Current research and potential benefits include an ability to help anxiety, post-traumatic stress disorder, and addiction with hallucinogen-assisted psychotherapy. Methods : We devised and administered a survey on 124 students at two college campuses, one small private college in the mid-Atlantic and one medium-sized public university in the Midwest of the United States. Results: Responses were similar [...]
Lire la suiteThe hyperassociative mind: The psychedelic experience and Merleau-Ponty’s “wild being” CSABA SZUMMER, LAJOS HORVÁTH, ATTILA SZABÓ, EDE FRECSKA and KRISTÓF ORZÓI Journal of Psychedelic Studies, 2017, 1, (2), pp. 55–64 DOI: 10.1556/2054.01.2017.006 Purpose : In contemporary phenomenology, Dieter Lohmar has suggested that the new task of phenomenological research is to analyze the “alternative representational systems” of fantasy. In line with this program, we propose that psychedelic experience could also be suitable subject to this project subsumed under the wider category of fantasy activity. The aim of this paper is to show that psychedelic experiences offer a favorable situation to study the imagination. Method : The [...]
Lire la suiteCan 3,4,-methylenedioxymethamphetamine therapy be used to treat alcohol use disorder ? Ben SESSA Journal of Psychedelic Studies, 2017, 1, (1), pp. 1–9 DOI: 10.1556/2054.01.2016.003 Treating people with alcohol use disorder has been an important target area for psychedelic research – both in the first studies of the 1950s and during the Psychedelic Renaissance of the last 10 years. To date, most studies have looked at the classical psychedelic drugs as adjuncts to psychotherapy; with attention paid to the psychospiritual aspect of the experience as a central therapeutic process in effecting abstinence from drinking. Psychotherapy assisted with 3,4,-methylenedioxymethamphetamine (MDMA) has never been explored for treating [...]
Lire la suiteTreating drug dependence with the aid of ibogaine: A qualitative study EDUARDO EKMAN SCHENBERG, MARIA ANGÉLICA DE CASTRO COMIS, JOÃO FELIPE MOREL ALEXANDRE, BRUNO DANIEL RASMUSSEN CHAVES, LUÍS FERNANDO TO´ FOLI and DARTIU XAVIER DA SILVEIRA Journal of Psychedelic Studies, 2017, 1, (1), pp. 10–19 DOI: 10.1556/2054.01.2016.002 Background : Substance use disorders are important contributors to the global burden of disease, but current treatments are not associated with high rates of recovery. The lack of approved and effective treatments is acutely problematic for psychostimulants like cocaine and crack cocaine. One promising alternative in the treatment of drug dependence in general and psychostimulants in particular [...]
Lire la suiteThe antiaddictive effects of ibogaine : A systematic literature review of human studies Rafael G. DOS SANTOS, José Carlos BOUSO and Jaime E. C. HALLAK Journal of Psychedelic Studies, 2017, 1, (1), pp. 20–28 DOI: 10.1556/2054.01.2016.001 Background and aims : Ibogaine is a naturally occurring hallucinogenic alkaloid with a therapeutic potential for reducing drug craving and withdrawal. To the best of our knowledge, no systematic review was previously performed assessing these effects. Thus, we conducted a systematic literature review of human studies assessing the antiaddictive effects of ibogaine. Methods : Papers published up to July 2, 2016 were included from PubMed, LILACS, and SciELO databases [...]
Lire la suiteDetoxification from methadone using low, repeated, and increasing doses of ibogaine : A case report CLARE WILKINS, RAFAEL G. DOS SANTOS, JORDI SOLÁ, MARC AIXALÁ, PEP CURA, ESTEFANÍA MORENO, MIGUEL ÁNGEL ALCÁZAR-CÓRCOLES, JAIME E. C. HALLAK and JOSÉ CARLOS BOUSO Journal of Psychedelic Studies, 2017, 1, (1), pp. 29–34 DOI: 10.1556/2054.01.2017.005 Background and aims : Ibogaine is a natural alkaloid that has been used in the last decades as an adjuvant for the treatment of opiate withdrawal. Despite the beneficial results suggested by animal studies and case series, there is a lack of clinical trials to assess the safety and efficacy of ibogaine. Moreover, [...]
Lire la suite